Mylan purchases Cold-Eeze brand from ProPhase Labs

Mylan has agreed a deal with ProPhase Labs to acquire global rights to the Cold-Eeze brand of cold remedies.

An established product line with a 20-year history, the Cold-Eeze range consists of a range of over-the-counter (OTC) cold remedies currently sold in the US market, including zinc-based lozenges, gummies, oral sprays, capsules and oral liquid dose forms.

Following the acquisition, Cold-Eeze will become Mylan's largest OTC brand in the US, strengthening its growth ambitions in this key market. The deal will encompass  all assets and other rights relating to the brand, including all businesses and international trademarks.

Mylan expects to complete the acquisition of the brand in the first quarter of 2017, subject to approval by ProPhase Labs' shareholders and other customary closing conditions.

Rajiv Malik, president of Mylan, said: "We look forward to continuing to expand our presence in the global OTC market through product acquisitions, marketing and line extensions, and opportunities to leverage our portfolio into new markets."

The brand will join a product portfolio that also includes product lines such as Dona, Betadine, Saugella, EndWarts, Froben, Ferrograd, MidNite and Vivarin.

With over 20 years of experience within the consumer market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current consumer roles we have available, you can search for the latest job roles, register your details, or contact the team today.